Interviews

Dr Joyce Ohm on the future of cancer care: identifying molecular drivers in every tumor to develop truly individualized, targeted therapies.

Erica Stringer-Reasor, MD, of UAB, discusses gedatolisib's FDA approval, its dual PI3K/mTOR mechanism, and what's next in HR+/HER2– breast cancer care.

MCED screening and broader genetic testing push community oncology toward prevention. Learn how practices adapt workflows, training, and follow-up for high-risk patients.

Danny Nguyen, MD, of City of Hope discusses bringing clinical trials to community oncology practices and the latest advances in lung cancer treatment.

Why genetic tests aren’t enough: learn how counseling, risk models, and ongoing follow-up shape personalized screening and cancer prevention.

Dr Joyce Ohm discusses the ethical questions raised by genome sequencing, from data ownership to reporting mutations of unknown significance.

Large genomic study shows BRCA2 breast cancers rapidly lose RB1, resisting CDK4/6 therapy; PARP inhibitors may work better and move to first line.

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

Community oncology expands hereditary cancer genetic testing with team-based counseling, trained clinicians, and structured follow-up pathways for complex results and high-risk families.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks drinking habits.

Joseph Mikhael, MD, MEd, discusses how the on-body injection option for isatuximab can improve convenience for community oncology staff and patients.

Genetic testing reshapes community oncology, expanding hereditary screening to guide personalized surveillance, identify high-risk families, and shift care toward cancer prevention.

Dr Joyce Ohm explains how sequencing tumor genomes reveals the mutations needed to design targeted cell and gene therapies for cancer patients.

Brian C. Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates after stem cell transplant.

Joyce Ohm, PhD, explains how fast genome sequencing now drives targeted cancer therapies, revealing mutations and resistance in real time.

Experts weigh newer ROS1 inhibitors like taletrectinib, highlighting long responses, fewer CNS/GI side effects, and trial challenges in rare NSCLC.

Brian C. Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life.

Menin inhibitors such as ziftomenib and revumenib target NPM1 and KMT2A AML, pushing precision therapy earlier with manageable toxicity.

Obesity rewires DCIS-to-IDC invasion via metabolic stress, inflammatory signaling and SULF2, revealing an immunosuppressive niche

In an interview, Joseph Mikhael, MD, MEd, discusses the impact of the approval of subcutaneous isatuximab and its on-body delivery system in multiple myeloma.

Learn how NPM1 MRD qPCR predicts relapse, shapes transplant decisions, and emerging trials test MRD negativity as a treatment target in AML.

Triplet therapy with ziftomenib, venetoclax, and azacitidine boosts responses in venetoclax‑naive NPM1‑mutated AML; phase 3 trials test frontline benefit.

Joseph Mikhael, MD, MEd, explains the function and potential benefits of the on-body injector now approved for use with isatuximab in multiple myeloma.

Chronic stress biomarker allostatic load links to higher under-50 cancer risk, offering a simple lab-based tool to improve prevention and screening.

Explore how allostatic load, using routine labs and vitals, may strengthen early-onset cancer risk prediction and guide earlier prevention in community oncology.

Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device.

MD Anderson trials test psilocybin therapy for head and neck cancer patients and survivors, aiming to curb suicide risk and ease treatment trauma.

KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable toxicity and longer responses.

KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses and guide future menin-based regimens.

Edgardo Santos, MD, discusses ROS1+ NSCLC treatment advances, taletrectinib data, toxicity profiles, and emerging therapies from recent Case-Based Roundtables.